We use essential cookies and third-party cookies for content.

The National Times - New Pokemon titles on horizon as 30th anniversary approaches

New Pokemon titles on horizon as 30th anniversary approaches

ECONOMY 27.02.2026
New Pokemon titles on horizon as 30th anniversary approaches
New Pokemon titles on horizon as 30th anniversary approaches / Photo: © AFP/File

Pikachu and friends are set to return to consoles in two new games next year, the Pokemon Company said Friday, as it celebrated 30 years of the monster-collecting franchise.

Change text size:

Set for release on Nintendo's latest Switch 2 console, "Pokemon Winds" and "Pokemon Waves" will see the fan-favourite critters return and new beasties emerge as players explore a colourful, tropical world stretching down to the ocean floor.

The Pokemon Company -- jointly owned by Nintendo, Japanese studio Game Freak and the Creatures company -- controls the brand for the franchise with more than 1,000 "pocket monsters" to date.

Longtime followers of the series will also be able to play the original games released for the portable Game Boy in 1996 on Switch, Nintendo said.

The next volley of Pokemon games was revealed just before the release of a new spinoff, "Pokopia", for Switch 2 on March 5.

Pokemon rapidly grew into a global phenomenon following the first titles' release on Game Boy.

Titles available on multiple consoles and mobile phones have sold more than 500 million copies over the franchise's 30-year history, according to figures from the Pokemon Company and Nintendo.

Originally inspired by traditional summer insect hunts in Japan, gameplay usually involves capturing and training fantastical "pocket monsters" resembling anything from mice to dragons, before sending them into battle against one another.

Beyond consoles, Pokemon has also spawned films, an animated series and the augmented reality mobile game "Pokemon Go".

In 2024, the brand generated $12 billion in revenues, according to specialist data firm License Global, more than toy giant Mattel.

A.Little--TNT

Featured

The "Everlasting Battery" Inside Your Joints:UConn Professor's Self-Powered Healing Material just Got Acquired

A material that turns your own movement into medicine has just landed a corporate home. PetVivo Holdings (OTCQX: PETV), a veterinary biotech and biomedical device company focused on treating osteoarthritis in dogs and horses, has acquired PiezoBioMembrane (PBM) — a startup built around a biodegradable implant that generates electricity from the everyday force of a joint in motion, and uses that charge to help regrow cartilage from the inside out. The material is the invention of Thanh Nguyen, a professor of mechanical engineering in UConn's College of Engineering, who founded PBM in 2021 to advance new implementation methods for his work with piezoelectric materials — substances that convert mechanical force into electrical energy. These materials are typically ceramics: hard, brittle, and poorly suited for medical use. But Nguyen's lab developed new forms that are so , flexible, and biodegradable, breaking down naturally within the body over time. wound healing, The materials have already shown strong potential across a range of medical applications, including tissue regeneration, implanted force sensors, and targeted drug delivery in tumor treatment. How It Works biodegradable ultrasound for In the case of arthritis, Nguyen explains, the piezoelectric materials function as an off-the-shelf product that can be implanted or injected directly into the ailing joint — with no drugs, chemicals, or cells required. The everyday force exerted on the joint generates a small electrical charge, which helps regrow healthy cartilage, mimicking the body's natural use of electricity to regenerate tissue. "The body can be electrically stimulated to regrow," Nguyen says. PBM's materials "act like a battery — an everlasting battery that works whenever there is a force applied, and vanishes safely inside the body over time." PetVivo's Vision for the Acquisition PetVivo Holdings CEO John Lai expressed enthusiasm for the merger's potential to improve the lives of companion animals globally. "PBM has developed a compelling functional biomaterials platform with the potential to support the development of multiple medical device and therapeutic product lines across both human and animal health markets," Lai said in a press release. "By combining PBM's scientific innovation with PetVivo's product development capabilities, commercialization experience, regulatory expertise, and public company infrastructure, we believe we can accelerate theadvancement of technologies that may serve as the foundation for numerous future products and strategic opportunities." For Nguyen, the deal is a chance to scale technology that could eventually benefit both animals and people. "PetVivo is an animal health company, but they do have a big passion: pushing the technology towards clinical trials for human use," Nguyen says. "That aligned perfectly with my passion for developing technology that has an impact on human life. That is why I am excited about this merger, which facilitates my passion." A Track Record of Innovation Nguyen's research sits at the intersection of medicine, micro/nanotechnology, and biomaterials. His inventions have earned him publications in prominent scientific journals and media coverage from outlets including NPR. Nguyen founded PBM during the COVID-19 pandemic, a er realizing the material he had developed could be used to create an especially effective, biodegradable face mask — one where the mechanical force of breathing generated an electrical charge that provided an extra layer of protection against viruses. PBM is not Nguyen's only venture in the acquisition pipeline. His other startup, Single-Time Microneedles (STM), is also currently undergoing an acquisition process. STM has pioneered stable, efficient vaccine delivery technology in the form of an adhesive patch. shelfNguyen's focus on biodegradable materials has translated into a remarkably diverse range of medical applications. He has received five R01 grants from the National Institutes of Health (NIH) supporting research in cartilage regeneration, bone regeneration, HIV antibody delivery systems, and biodegradable ultrasound technology to boost the effectiveness of chemotherapy for brain cancer. "Whatever we are working on, we want to show that it works very well in vitro and in vivo," Nguyen says. "Then, when we are at the point of commercialization, we set up a startup or license the technology — or maybe team up with an industry partner." Thanh Nguyen is a professor of mechanical engineering in UConn's College of Engineering. (Courtesy of Thanh Nguyen

Octrado introduces its proprietary trading offering: "Your Skill. Our Capital"

Infrastructure, transparent rules and clear legal boundaries positioned as the core of the funded-account model

Could gas prices return to 2022 highs on US-Iran war?

European gas prices have more than doubled owing to the US-Iran war, just as Europe needs to replenish its reserves ahead of winter.

CapTLX Expands Institutional-Oriented Platform for Access to U.S. Capital Markets

CapTLX, the securities trading and investment platform operated by CHAINLION TECH LTD, today announced the continued expansion of its technology infrastructure for qualified investors and institutional market participants seeking structured access to U.S. equity and private capital markets.

Change text size: